Results 31 to 40 of about 6,610 (196)

Frequency, Burden and Pathogens of Acute Respiratory Illness in Very Preterm Infants During Infancy

Acta Paediatrica, EarlyView.
ABSTRACT Aim To describe the frequency, burden, and pathogen profile of acute respiratory illnesses (ARIs) in very preterm infants during the first year after neonatal intensive care unit (NICU) discharge. Methods Very preterm infants were followed prospectively (August 2015–January 2017) with monthly assessments of symptoms, medication use, and ...
Patricia De Gouveia Belinelo, Nada Townsi, Naomi R. Hemy, Chisha T. Sikazwe, David W. Smith, Benjamin Stoecklin, J. Jane Pillow, Graham L. Hall, Ingrid A. Laing, Shannon J. Simpson   +9 more
wiley   +1 more source

Palivizumab nella profilassi del virus respiratorio sinciziale: analisi di impatto sul budget del SSN italiano [PDF]

, 2011
Palivizumab is a monoclonal antibody to RSV that has been shown to significantly reduce the frequency of hospitalisations for RSV infection, in at-risk populations. However, payers are concerned about the budgetary impact of adopting palivizumab.
Roggeri, Daniela
core   +1 more source

A Confirmatory, Dual Center Nonhuman Primate Study on the Efficacy of Novel Oropharyngeal Spray Immunization With an Adenoviral Vector Vaccine Against RSV—Important Lessons Learned

Journal of Medical Primatology, Volume 55, Issue 6, December 2026.
ABSTRACT Background In a randomized, blinded, dual center study across two European primate research facilities, we evaluated the immunogenicity and protective efficacy of a DNA prime—oropharyngeal adenoviral boost vaccination strategy against respiratory syncytial virus (RSV).
Matthias Tenbusch, Gerrit Koopman, Petra Mooij, Berit Roshani, Pascal Irrgang, Dennis Lapuente, Ivanela Kondova, Willy M. Bogers, Edmond J. Remarque, Ramona Vestweber, Samuel Alberto Merida Ruiz, Nadine Krüger, Sebastian Meyer, Olaf Gefeller, Christiane Stahl‐Hennig, Klaus Überla   +15 more
wiley   +1 more source

Pulmonary Deposition of Radionucleotide-Labeled Palivizumab: Proof-of-Concept Study

Frontiers in Pharmacology, 2020
ObjectiveCurrent prevention and/or treatment options for respiratory syncytial virus (RSV) infections are limited as no vaccine is available. Prophylaxis with palivizumab is very expensive and requires multiple intramuscular injections over the RSV ...
Anushi E. Rajapaksa, Anushi E. Rajapaksa, Anushi E. Rajapaksa, Lien Anh Ha Do, Lien Anh Ha Do, Darren Suryawijaya Ong, Darren Suryawijaya Ong, Magdy Sourial, Duncan Veysey, Richard Beare, Richard Beare, William Hughes, William Yang, Robert J. Bischof, Robert J. Bischof, Amarin McDonnell, Peter Eu, Leslie Y. Yeo, Paul V. Licciardi, Paul V. Licciardi, Edward K. Mulholland, Edward K. Mulholland, Edward K. Mulholland   +22 more
doaj   +1 more source

Palivizumab Exposure and the Risk of Autoimmune Disease:A Cross-National Cohort Study

, 2016
BACKGROUND: Treatment with biologic pharmaceuticals may be associated with an increased risk of immune-mediated disease. Palivizumab is a humanized monoclonal antibody designed to provide passive immunity against respiratory syncytial virus infection ...
Linder, Marie, Ravn, Henrik, Haerskjold, Ann, Henriksen, Lonny, Thomsen, Simon Francis, Stensballe, Lone Graff, Kieler, Helle, Haerskjold, A, Thomsen, SF, Kieler, H, Linder, M,, Henriksen, L, Stensballe, LG, Ravn, H   +13 more
core   +1 more source

Palivizumab coverage rates among moderate-to-late preterm infants in Korea: a nationwide cross-sectional study [PDF]

Epidemiology and Health
OBJECTIVES Since October 2016, Korea has implemented a national reimbursement program for palivizumab aimed at moderate-to-late preterm (MLPT) infants born between 32 0/7 weels and 35 6/7 weeks of gestation during the respiratory syncytial virus (RSV ...
Seungyeon Kim, Saram Lee, Young June Choe, Ju Sun Heo   +3 more
doaj   +1 more source

RSV Disease Among Hospitalized Children: Second vs. First Year of Life Multicenter Study

Influenza and Other Respiratory Viruses, Volume 20, Issue 11, November 2026.
ABSTRACT Background Respiratory syncytial virus (RSV) is a leading cause of pediatric hospitalization, yet data on children hospitalized with RSV in their second year of life are limited. Objective To compare clinical characteristics and management practices of children hospitalized with RSV during their second versus first year of life.
Keren Armoni Domany, Inbal Golan‐Tripto, Nitzan Burrack, Kamal Masarweh, Michal Gur, Mika Rochman, Moria Be'er, Dario Prais, Meirav Mor, Moran Weinberger Opek, Elias Nasrallah, Orli Megged, Rachel Shatzman Steuerman, Michal Stein, Zohar Steinberg, Shereen Shehadeh, Aharona Glatman‐Freedman, Diana Tasher   +17 more
wiley   +1 more source

Universal palivizumab prophylaxis for children with Down syndrome in Japan: analysis with interrupted time-series

Human Vaccines & Immunotherapeutics, 2021
Down syndrome (DS) is an independent risk factor for severe respiratory syncytial virus (RSV) infection. Palivizumab – passive immunization for RSV – is the only pharmacological measure for preventing severe disease.
Masato Takeuchi, Koji Kawakami
doaj   +1 more source

Validation of Small‐Molecule Entry Inhibitors Targeting the Respiratory Syncytial Virus

ChemMedChem, Volume 21, Issue 20, 28 October 2026.
Respiratory syncytial virus (RSV) remains a major cause of severe respiratory disease, while effective treatments for acute infection are still limited. We screened small‐molecule RSV entry inhibitors and investigated promising hits through resynthesis and antiviral testing.
Christina Karhan, Svenja M. Sake, Melanie Urbanek‐Quaing, Diletta Bergamo, Jessica Rückert, Jiabin Huang, Christina Grethe, Antonia P. Gunesch, Anne Kühnel, Birthe Reinecke, Nicole Fischer, Thomas F. Schulz, Thomas Pietschmann, Anna K. H. Hirsch   +13 more
wiley   +1 more source

Intermediate‐Phenotype ABCA3 Deficiency Caused by Compound Heterozygous Variants Presenting as Persistent Respiratory Failure and Systemic Hypertension Since Birth in a Term Infant: A Case Report

Clinical Case Reports, Volume 14, Issue 10, October 2026.
ABSTRACT ABCA3 deficiency should be suspected in term infants with persistent respiratory distress from birth. This case highlights how early whole‐exome sequencing established the diagnosis after extensive investigations, identified an intermediate phenotype caused by compound heterozygous variants, and guided targeted multidisciplinary management.
Ammir Abuzahra, Mohamad Abu Mayalah, Mahmoud Abdelrazzaq Abu Mayaleh, Amani Daabes, Rafad Y. Dweik, Abdelrazzaq Abu Mayaleh   +5 more
wiley   +1 more source